Chemical Exploration of a Highly Selective Scaffold with Activity against Intracellular Mycobacterium tuberculosis

被引:1
|
作者
Njikan, Samuel [1 ,2 ]
Ahmed, Sara [1 ,2 ]
Manning, Alyssa [1 ]
Awasthi, Divya [1 ]
Ovechkina, Yulia [1 ,2 ]
Chowdhury, Sultan [1 ,2 ]
Butts, Arielle [1 ,2 ]
Parish, Tanya [1 ,2 ]
机构
[1] Infect Dis Res Inst, Seattle, WA 98102 USA
[2] Seattle Childrens Res Inst, Ctr Global Infect Dis Res Seattle, Seattle, WA 98101 USA
来源
MICROBIOLOGY SPECTRUM | 2022年 / 10卷 / 03期
基金
美国国家卫生研究院;
关键词
high-content analysis; Mycobacterium tuberculosis; phenotypic screening; antibacterial drug discovery; DRUG DISCOVERY; DERIVATIVES; SURVIVAL; GENES; UREA;
D O I
10.1128/spectrum.01161-22
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Mycobacterium tuberculosis is responsible for the highest number of deaths from a bacterial pathogen, with >1.5 million in 2020. M. tuberculosis is a sophisticated pathogen that can replicate inside immune cells. There is an urgent need for new drugs to combat M. tuberculosis and to shorten therapy from 6 to 24 months. We previously identified a phenylthiourea series with activity against intracellular Mycobacterium tuberculosis using a high-throughput, high-content assay. We conducted a catalog structure-activity relationship study with a collection of 35 analogs. We identified several thiourea derivatives with excellent potency against intracellular bacteria and good selectivity over eukaryotic cells. Compounds had much lower activity against extracellular bacteria, which was not increased by using cholesterol as the sole carbon source. Compounds were equally active against strains with mutations in QcrB or MmpL3, thereby excluding common, promiscuous targets as the mode of action. The phenylthiourea series represents a good starting point for further exploration to develop novel antitubercular agents. IMPORTANCE Mycobacterium tuberculosis is responsible for the highest number of deaths from a bacterial pathogen, with >1.5 million in 2020. M. tuberculosis is a sophisticated pathogen that can replicate inside immune cells. There is an urgent need for new drugs to combat M. tuberculosis and to shorten therapy from 6 to 24 months. We have identified a series of molecules that inhibit the growth of M. tuberculosis inside macrophages; we tested a number of derivatives to link structural features to biological activity. The compounds are likely to have novel mechanism of action and so could be developed as new agents for drug-resistant tuberculosis.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Phenotypic-Based Discovery and Exploration of a Resorufin Scaffold with Activity against Mycobacterium tuberculosis
    Tran, Eric
    Cheung, Chen-Yi
    Li, Lucy
    Carter, Glen P.
    Gable, Robert W.
    West, Nicholas P.
    Kaur, Amandeep
    Gee, Yi Sing
    Cook, Gregory M.
    Baell, Jonathan B.
    Joerg, Manuela
    CHEMMEDCHEM, 2024,
  • [2] Higher activity of morphazinamide over pyrazinamide against intracellular Mycobacterium tuberculosis
    Teyssier, L
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2001, 5 (04) : 386 - 386
  • [3] Efficient Synthesis of Benzothiazinone Analogues with Activity against Intracellular Mycobacterium tuberculosis
    Richter, Adrian
    Narula, Gagandeep
    Rudolph, Ines
    Seidel, Ruediger W.
    Wagner, Christoph
    Av-Gay, Yossef
    Imming, Peter
    CHEMMEDCHEM, 2022, 17 (06)
  • [4] Benzene Amide Ether Scaffold is Active against Non-replicating and Intracellular Mycobacterium tuberculosis
    Ahmed, Sara
    Chowdhury, Sultan
    Gomez, James
    Hung, Deborah T.
    Parish, Tanya
    ACS INFECTIOUS DISEASES, 2023, 9 (10): : 1981 - 1992
  • [5] Polycytotoxic T cells mediate antimicrobial activity against intracellular Mycobacterium tuberculosis
    Zumwinkel, Marc
    Chirambo, Aaron
    Zaehnle, Markus
    Buerger, Max
    Grieshober, Mark
    Romahn, Vincent
    Mwandumba, Henry
    Stenger, Steffen
    INFECTION AND IMMUNITY, 2025, 93 (01)
  • [6] Synthesis of indolizine derivatives with selective antibacterial activity against Mycobacterium tuberculosis
    Gundersen, Lise-Lotte
    Charnock, Colin
    Negussie, Ayele Hailu
    Rise, Frode
    Teklu, Solomon
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2007, 30 (01) : 26 - 35
  • [7] Modulation of the Specificity of Carbapenems and Diazabicyclooctanes for Selective Activity against Mycobacterium tuberculosis
    Barnier, Jean-Philippe
    Saidjalolov, Saidbakhrom
    Bouchet, Flavie
    Mayer, Louis
    Edoo, Zainab
    Sayah, Ines
    Iannazzo, Laura
    Etheve-Quelquejeu, Melanie
    Mainardi, Jean-Luc
    Braud, Emmanuelle
    Arthur, Michel
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (09)
  • [8] Quinoxaline Moiety: A Potential Scaffold against Mycobacterium tuberculosis
    Montana, Marc
    Montero, Vincent
    Khoumeri, Omar
    Vanelle, Patrice
    MOLECULES, 2021, 26 (16):
  • [9] Lysozyme: an endogenous antimicrobial protein with potent activity against extracellular, but not intracellular Mycobacterium tuberculosis
    Maier, Felix Immanuel
    Klinger, David
    Grieshober, Mark
    Noschka, Reiner
    Rodriguez, Armando
    Wiese, Sebastian
    Forssmann, Wolf-Georg
    Staendker, Ludger
    Stenger, Steffen
    MEDICAL MICROBIOLOGY AND IMMUNOLOGY, 2024, 213 (01)
  • [10] A high content microscopy assay to determine drug activity against intracellular Mycobacterium tuberculosis
    Manning, Alyssa J.
    Ovechkina, Yulia
    McGillivray, Amanda
    Flint, Lindsay
    Roberts, David M.
    Parish, Tanya
    METHODS, 2017, 127 : 3 - 11